Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Articles

Options facilitate increased durability for patients with retinal degeneration.

Two new retinal surgical procedures for wet AMD: PDS and RGX-314

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

Severe COVID-19 infections associated with retinal, choroidal microvascular lesions

Videos

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Results from phase 2b study of AR-15512 for the treatment of dry eye

The Children’s Vision Equity Alliance was created to improve access in children’s vision and eye health, working to advance equity in children’s vision and eye health through education, policies and partnerships.

Prevent Blindness: National Center for Children’s Vision and Eye Health forges Children’s Vision Equity Alliance

Verana Health showcases the VeraQ quality measures dashboard  for the IRIS registry report at AAO 2021.

New quality measures dashboard from Verana Health unveiled at AAO

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Wearable diagnostic platform addresses gaps in vision care

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis. 

Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

FDA approves first biosimilar product for retinal diseases

Improvements are seen after gene therapy for Leber congenital amaurosis.

Study examines VR orientation, mobility testing for patients with inherited retinal diseases

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

FDA approves first biosimilar product for retinal diseases

Study examines VR orientation, mobility testing for patients with inherited retinal diseases

New sustained-release anti-VEGF formula proves safe and effective in phase 1 trials